48
Participants
Start Date
June 6, 2023
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2025
TTP488
Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.
ddAC/ddT
Dose dense doxorubicin plus cyclophosphamide followed by paclitaxel (ddAC/ddT) for 8 cycles, administered per USPI (Unites States Prescribing Information) Label
TC
Docetaxel plus cyclophosphamide (TC) for 4-6 cycles, administered per USPI (Unites States Prescribing Information) Label
TCHP
Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label
Chemotherapy regimen that includes ddAC
can include: (1) weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide, administered per USPI (Unites States Prescribing Information) Label
RECRUITING
Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
RECRUITING
Medstar Washington Hospital Center, Washington D.C.
RECRUITING
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Georgetown University
OTHER